Multiple sclerosis and related disorders · 2026
Between-hospital variation in discontinuation of treatment with dimethyl fumarate in multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Norborg Hilde, Bramow Stephan, Aarseth Jan Harald, Mannseth Janne, Grytten Nina, Flemmen Heidi Øyen, Øksendal Nina, Høglund Rune Alexander, Lian Kathrine, Bjørnå Ingrid, Roar Malte, Nielsen Amalie Rhode Høgh, Berg Jonas Munksgaard, Stilund Morten, Schäfer Jakob, Frederiksen Jette, Ashna Said Nasim, Jensen Henrik Boye, Kant Matthias, Theódorsdóttir Asta, Magyari Melinda, Schlosser Louise Mose, Buch Louise Parker, Myhr Kjell-Morten, Sejbaek Tobias, Wergeland Stig
Аннотация
BACKGROUND: In multiple sclerosis (MS), switching disease modifying treatment is associated with higher relapse rate, healthcare expenses, disease burden, and lower quality of life. We compared drug discontinuation rates of dimethyl fumarate (DMF) between hospitals in Denmark and Norway.
METHOD: Data from national MS registries were analyzed, adjusting for sex, age, disease duration, Expanded Disability Status Scale, and baseline relapses. Between-hospital variation was assessed using median hazard ratios (MHR).
RESULTS: 3368 patients with relapsing-remitting MS started DMF at all clinics in Denmark (n = 14) and at a subset of clinics in Norway (n = 6). A median of 44% discontinued DMF. Predictors for discontinuation were female sex, younger age, higher EDSS and number of relapses at baseline. There was a significant difference in the risk of discontinuation between hospitals. The MHR for discontinuation because of treatment failure attributed to treating hospital was 1.51(SE 0.120, p < 0.001) in Norway and 1.34 (SE 0.055, p < 0.001) in Denmark.
CONCLUSION: Discontinuation rates of DMF in MS varies between hospitals, independent of patient characteristics.
METHOD: Data from national MS registries were analyzed, adjusting for sex, age, disease duration, Expanded Disability Status Scale, and baseline relapses. Between-hospital variation was assessed using median hazard ratios (MHR).
RESULTS: 3368 patients with relapsing-remitting MS started DMF at all clinics in Denmark (n = 14) and at a subset of clinics in Norway (n = 6). A median of 44% discontinued DMF. Predictors for discontinuation were female sex, younger age, higher EDSS and number of relapses at baseline. There was a significant difference in the risk of discontinuation between hospitals. The MHR for discontinuation because of treatment failure attributed to treating hospital was 1.51(SE 0.120, p < 0.001) in Norway and 1.34 (SE 0.055, p < 0.001) in Denmark.
CONCLUSION: Discontinuation rates of DMF in MS varies between hospitals, independent of patient characteristics.